RIDDLE&CODE
13.4.2021 10:17:12 CEST | Business Wire | Press release
RIDDLE&CODE FinTech Solutions, an innovative European company that empowers financial institutions to handle all aspects of digital asset management, announced today that LiteBit, the leading Dutch cryptocurrency exchange, has chosen its Token Management Platform (TMP) to scale infrastructure, respond to regulatory requirements and provide advanced capabilities to its growing customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005034/en/
Over the last few years, the European Union has significantly tightened its regulations on crypto service providers, including the recently updated 5th Anti-Money Laundering Directive (AMLD5). The newly implemented AMLD5 guidelines oblige service providers such as crypto exchanges and custodians to adhere to the same regulatory provisions as traditional financial institutions.
“The Dutch implementation of the regulations currently goes beyond EU guidelines and calls for extensive identification of customers and monitoring of transactions as well as extensive reporting and audit capabilities,” said Berit Fuss, Director of FinTech Solutions at RIDDLE&CODE. “These requirements have turned out to be quite burdensome and have forced several crypto-related businesses to close or leave the Netherlands.”
“Crypto exchanges across the industry are prioritising compliance with regulatory obligations. LiteBit is no exception,” said Arthur Van Lier, LiteBit’s COO. “The partnership with RIDDLE&CODE and the use of the cutting-edge TMP enables us to be compliant with both current and future regulations. But regulatory frameworks aren’t the only ones evolving,” he added. “At the moment, Decentralised Finance (DeFi) is one of the fastest-growing sectors in the crypto industry. However, due to the complexity of the applications and the efforts required to support several token protocols, many market players struggle to innovate and accommodate the integration of DeFi capabilities. With the TMP, we can benefit from these new business models and scale our operational capabilities.”
The TMP provides the Dutch exchange with a robust and transparent foundation for:
- Responding to the most pressing demands in an ever-changing regulatory environment, including AML/CFT requirements, customer due diligence, Know-Your-Customer (KYC) procedures and more.
- Scaling its operations by creating unlimited segregated accounts for its customers and automating certain processes to reduce the burden on the operational teams.
- Being flexible enough to offer DeFi services such as staking or voting on popular networks like Polkadot and Ethereum.
The Token Management Platform is the next generation of RIDDLE&CODE’s institutional-grade digital asset management solution. The cloud-based platform manages all aspects of key generation, custody, AML, regulatory compliance and token management. Accepted by the Swiss financial market authorities, the TMP is fully auditable and compliant with financial regulations, allowing clients to fulfill all transparency requirements in line with financial regulations and internal compliance policies.
“We are thrilled to work with LiteBit, our first crypto exchange customer,” said Alexander Koppel, CEO of RIDDLE&CODE. “This strategic partnership allows us to enter the Dutch market and help LiteBit in its journey to full regulatory compliance and expansion across Europe.”
RIDDLE&CODE FinTech Solutions
RIDDLE&CODE FinTech solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, builds hardware and software stacks that empower funds, crypto exchanges and regulated financial institutions to manage all aspects of key generation, custody, AML, regulatory compliance and token management with unmatched versatility and security.
LiteBit
LiteBit is a platform that makes trading in crypto safe, simple and personal. Its aim is to be the most customer-friendly and reliable platform in Europe. LiteBit supports investors in buying, selling and managing crypto, such as Bitcoin, Ethereum and more than 50 other types of coins.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom